The Anal Cancer Therapeutics Market is Forecast to Show Static Growth Until 2019

Wednesday 18 April 2012, Amsterdam

The “Anal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019” report is an essential source of information and analysis on the global anal cancer therapeutics market. The report identifies the key trends shaping and driving the global anal cancer therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anal cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Anal Cancer Therapeutics Market is Forecast to Show Static Growth Until 2019

The report estimates that the global anal cancer therapeutics market was worth $31.20m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 1.20% during 2006-2011. During 2011-2019, the market is expected to record a CAGR of 1.15%, from $31.20m in 2011 to $34.2m in 2019. The current treatment option for anal cancer includes two generic regimens, 5-Florouracil (5-FU) with mitomycin for localized cancer and 5-FU in combination with cisplatin for patients with metastatic anal cancer. The static growth of the market is primarily due to slow increase in the incidence rates and lack of new product approvals during the forecast period. Due to these factors, the anal cancer therapeutics market is expected to show static growth until 2019.

In December 2010, the FDA approved Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) in the US for the prevention of anal cancer and associated pre-cancerous lesions due to HPV types 6, 11, 16, and 18 in individuals aged nine through 26 years. Gardasil is a prophylactic vaccine used for the prevention of anal cancer in both males and females.

Moderate Unmet Need Continues to Challenge the Pipeline Drugs

This analysis shows that the current market landscape is weak, as the anal cancer therapeutics market is dominated by generic regimens. These regimens have only moderate levels of efficacy and safety, and as a result there is moderate unmet need in the anal cancer therapeutics market. Thus, the current market offers considerable potential for pipeline drugs that are stronger in terms of efficacy and safety than the current market products. However, considering the fact that all of the pipeline molecules are first-in-class and are in the early stages of development, the anal cancer therapeutic market will continue to remain dominated by the existing treatment options during the forecast period.

Pipeline Offers No Hope for Anal Cancer Therapeutics

This analysis of the entire pipeline landscape shows that the late stage pipeline does not offer any immediate hope for patients with anal cancer. The anal cancer therapeutics pipeline does not hold any promising molecules in the late phase of development. There are no molecules in Phase III of development. There are three molecules in Phase II and one molecule each in Phase I and the preclinical stages of development. However, as these molecules are not expected to receive approval in the forecast period (2011-2019) they are unlikely to have an impact on the anal cancer therapeutics market.